High-Dose Daptomycin Is Well Tolerated via 2-Minute IV Push Administration. (August 2021)

• Record Type: Journal Article
• Authors: Gill, Christian M.; Kenney, Rachel M.; Makowski, Charles T.; Davis, Susan L.
• Is Part Of: Hospital pharmacy. Volume 56:Number 4(2021)
• Page Start: 328
• Page End: 331
• Publication Date: 2021-08
• Subjects: daptomycin -- infusion intravenous -- medication safety -- pharmaceutical preparations; Hospital pharmacies -- Periodicals; Pharmacy Service, Hospital; Hospital pharmacies; Periodicals; Periodicals; 615.1
• DOI: 10.1177/0018578719897076
• Languages: English
• ISSNs: 0018-5787

Abstract

Background: The purpose of this study was to evaluate the safety of administering high-dose daptomycin (HDD; > 6 mg/kg actual body weight) as a 2-minute intravenous (IV) push (IVP) compared to traditional 30-minute IV piggyback (IVPB) infusion. Methods: Retrospective cohort study comparing patients receiving HDD as an IVP or IVPB infusion. The primary outcome was the proportion of patients with a documented infusion-related reaction (IRR) to daptomycin. Results: Three hundred patients were included in the final analysis, 200 patients received IVP, and 100 patients received IVPB representing a total of 1697 administrations. Median (IQR) daptomycin dose was IVP 700 mg (550-900) and IVPB 700 mg (600-900), with mg/kg doses of 8.2 (7.9-10) and 8.3 (8-10), respectively. After adjudication, IRR occurred in 1% of subjects in each treatment group. Conclusions: This study provides data in more than 1100 administrations of HDD administered via IVP. Infusion-related reactions were documented in 1% of patients regardless of infusion method, suggesting comparable safety to traditional infusion methods. This practice may be useful during fluid shortage and in the outpatient setting.